Journal of Computer-Aided Molecular Design

, Volume 24, Issue 9, pp 759–769 | Cite as

In silico analysis of the histaprodifen induced activation pathway of the guinea-pig histamine H1-receptor

Article
First Online:
Received:
Accepted:

Abstract

The binding of (partial) agonists in the binding pocket of biogenic amine receptors induces a conformational change from the inactive to the active state of the receptors. There is only little knowledge about the binding pathways of ligands into binding pocket on molecular level. So far, it was not possible with molecular dynamic simulations to observe the ligand binding and receptor activation. Furthermore, there is nearly nothing known, in which state of ligand binding, the receptor gets activated. The aim of this study was to get more detailed insight into the process of ligand binding and receptor activation. With the recently developed LigPath algorithm, we scanned the potential energy surface of the binding process of dimeric histaprodifen, a partial agonist at the histamine H1-receptor, into the guinea pig histamine H1-receptor, taking also into account the receptor activation. The calculations exhibited large conformational changes of Trp6.48 and Phe6.55 during ligand binding and receptor activation. Additionally, conformational changes were also observed for Phe6.52, Tyr6.51 and Phe6.44. Conformational changes of Trp6.48 and Phe6.52 are discussed in literature as rotamer toggle switch in context with receptor activation. Additionally, the calculations indicate that the binding of dimeric histaprodifen, accompanied by receptor activation is energetically preferred. In general, this study gives new, theoretical insights onto ligand binding and receptor activation on molecular level.

Keywords

Guinea-pig Histamine H1-Receptor G protein-coupled receptor Inactive conformation Active conformation Receptor activation LigPath 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We thank the DFG (Deutsche Forschungsgemeinschaft) for further support of this project.

References

  1. 1.
    Pierce KL, Premont RT, Lefkowitz RJ (2002) Nat Rev Mol Cell Biol 9:639–650CrossRefGoogle Scholar
  2. 2.
    Kristiansen K (2004) Pharmacol Ther 103:21–80CrossRefGoogle Scholar
  3. 3.
    Gether U, Kobilka BK (1998) J Biol Chem 273:17979–17982CrossRefGoogle Scholar
  4. 4.
    Kobilka BK, Deupi X (2007) Trends Pharmacol Sci 28:397–406CrossRefGoogle Scholar
  5. 5.
    Kobilka BK (2007) Biochim Biophys Acta 1768:794–807CrossRefGoogle Scholar
  6. 6.
    Kobilka BK, Deupi X (2007) Trends Pharm Sci 28:397–406CrossRefGoogle Scholar
  7. 7.
    Bartfai T, Benovic J, Bockaert J, Bond RA, Bouvier M, Christopoulos A, Civelli O, Devi LA, George SR, Inui A, Kobilka BK, Leurs R, Neubig R, Pin JP, Quirion R, Roques BP, Sakmar TP, Seifert R, Stenkam RE, Strange PG (2004) Nat Rev Drug Discov 3:577–626CrossRefGoogle Scholar
  8. 8.
    Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK (2001) Proc Natl Acad Sci USA 98:5997–6002CrossRefGoogle Scholar
  9. 9.
    Xie SX, Ghorai P, Ye QZ, Buschauer A, Seifert R (2006) J Pharmacol Exp Ther 317:139–146CrossRefGoogle Scholar
  10. 10.
    Wittmann HJ, Seifert R, Strasser A (2009) Mol Pharmacol 76:25–37CrossRefGoogle Scholar
  11. 11.
    Bhattacharya S, Hall SE, Li H, Vaidehi N (2008) Biophys J 84:2027–2042CrossRefGoogle Scholar
  12. 12.
    Bhattacharya S, Hall SE, Vaidehi N (2008) J Mol Biol 382:539–555CrossRefGoogle Scholar
  13. 13.
    Schertler GF (2005) Curr Opin Struct Biol 15:408–415CrossRefGoogle Scholar
  14. 14.
    Gabilondo AM, Cornelius K, Lohse MJ (1996) Eur J Pharmacol 307:243–250CrossRefGoogle Scholar
  15. 15.
    Liapakis G, Ballesteros JA, Papchristou S, Chan WC, Chen X, Javitch JA (2000) J Biol chem 275:37779–37788CrossRefGoogle Scholar
  16. 16.
    Chen S, Lin F, Xu M, Rie RP, Novotny J, Graham RM (2002) Biochemistry 41:6045–6053CrossRefGoogle Scholar
  17. 17.
    Jongejan A, Bruysters M, Ballesteros JA, Haaksma E, Bakker RA, Pardo L, Leurs R (2005) Nat Chem Biol 1:98–103CrossRefGoogle Scholar
  18. 18.
    Javitch JA, Fu D, Liapakis G, Chen J (1997) J Biol Chem 272:18546–18549CrossRefGoogle Scholar
  19. 19.
    Rasmussen SGF, Jensen AD, Liapakis G, Ghanouni P, Javitch JA, Gether U (1999) Mol Pharmacol 56:175–184Google Scholar
  20. 20.
    Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA (2002) J Biol Chem 277:40989–40996CrossRefGoogle Scholar
  21. 21.
    Vilardaga JP, Steinmeyer R, Harms GS, Lohse MJ (2005) Nat Chem Biol 1:25–28CrossRefGoogle Scholar
  22. 22.
    Farrens D, Altenbach C, Yan K, Hubbell W, Khorana HG (1996) Science 274:768–770CrossRefGoogle Scholar
  23. 23.
    Ward SDC, Hamdan FF, Bloodworth LM, Wess J (2002) J Biol Chem 277:2247–2257CrossRefGoogle Scholar
  24. 24.
    Dunham TD, Farrens DL (1999) J Biol Chem 274:1683–1690CrossRefGoogle Scholar
  25. 25.
    Altenbach C, Klein-Seetharaman J, Cai K, Khorana HG, Hubbell WL (2001) Biochemistry 40:15493–15500CrossRefGoogle Scholar
  26. 26.
    Shen J, Li W, Liu G, Tang Y, Jiang H (2009) J Phys Chem B 113:10436–10444CrossRefGoogle Scholar
  27. 27.
    Wang T, Duan Y (2009) J Mol Biol 392:1102–1115CrossRefGoogle Scholar
  28. 28.
    Straßer A, Wittmann HJ (2007) J Mol Model 13:209–218CrossRefGoogle Scholar
  29. 29.
    Straßer A, Wittmann HJ (2007) J Comput Aided Mol Des 21:499–509CrossRefGoogle Scholar
  30. 30.
    Bakker RA, Jongejan A, Sansuk K, Hacksell U, Timmerman H, Brann MR, Weiner DM, Pardo L, Leurs R (2008) Mol Pharmacol 73:94–103CrossRefGoogle Scholar
  31. 31.
    Straßer A, Wittmann HJ, Seifert R (2008) J Pharmacol Exp Ther 326:783–791CrossRefGoogle Scholar
  32. 32.
    Straßer A, Wittmann HJ, Kunze M, Elz S, Seifert R (2009) Mol Pharmacol 75:454–465CrossRefGoogle Scholar
  33. 33.
    Bruysters M, Jongejan A, Gillard M, van de Manakker F, Bakker R, Chatelain P, Leurs R (2005) Mol Pharmacol 67:1045–1052CrossRefGoogle Scholar
  34. 34.
    Jongejan A, Leurs R (2005) Arch Pharm Chem Life Sci 338:248–259CrossRefGoogle Scholar
  35. 35.
    Bruysters M, Pertz HH, Teunissen A, Bakker RA, Gillard M, Chatelain P, Schunack W, Timmerman H, Leurs R (2004) 487:55–63Google Scholar
  36. 36.
    Menghin S, Pertz HH, Kramer K, Seifert R, Schunack W, Elz S (2003) J Med Chem 46:5458–5470CrossRefGoogle Scholar
  37. 37.
    Seifert R, Wenzel Seifert K, Bürckstümmer T, Pertz HH, Schunack W, Dove S, Buschauer A, Elz S (2003) J Pharmacol Exp Ther 305:1104–1115CrossRefGoogle Scholar
  38. 38.
    Straßer A, Striegl B, Wittmann HJ, Seifert R (2008) J Pharmacol Exp Ther 324:60–71CrossRefGoogle Scholar
  39. 39.
    Ballesteros JA, Shi L, Javitch JA (2001) Mol Pharmacol 60:1–19Google Scholar
  40. 40.
    Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M (2000) Science 289:739–745CrossRefGoogle Scholar
  41. 41.
    Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, BK Kobilka, Stevens RC (2007) Science 318:1258–1265CrossRefGoogle Scholar
  42. 42.
    Rasmussen SGF, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VRP, Sanishvili R, Fischetti RF, Schertler GFX, Weis WI, Kobilka BR (2007) Nature 450:383–387CrossRefGoogle Scholar
  43. 43.
    Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SGF, Thian FS, Kobilka BS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK (2007) Science 318:1266–1273CrossRefGoogle Scholar
  44. 44.
    Niv MY, Skrabanek L, Filizola M, Weinstein H (2006) J Comput Aided Mol Des 20:437–448CrossRefGoogle Scholar
  45. 45.
    Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, Ernst OP (2008) Nature 455:497–503CrossRefGoogle Scholar
  46. 46.
    Oostenbrink C, Villa A, Mark AE, van Gunsteren WF (2004) J Comput Chem 25:1656–1676CrossRefGoogle Scholar
  47. 47.
    van der Spool D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC (2005) J Comput Chem 26:1701–1718CrossRefGoogle Scholar
  48. 48.
    Crocker E, Eilers M, Ahuja S, Hornak V, Hirshfeld A, Sheves M, Smith SO (2006) J Mol Biol 357:163–172CrossRefGoogle Scholar
  49. 49.
    Singh R, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Guarnieri F (2002) J Peptide Res 60:357–370CrossRefGoogle Scholar
  50. 50.
    Colson AO, Perlman JH, Jinsi-Parimoo A, Nussenzveig DR, Osman R, Gershengorn MC (1998) Mol Pharmacol 54:968–978Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  1. 1.Department of Pharmaceutical and Medicinal Chemistry, Faculty of Chemistry and PharmacyUniversity of RegensburgRegensburgGermany
  2. 2.Faculty of Chemistry and PharmacyUniversity of RegensburgRegensburgGermany

Personalised recommendations